BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cytognos, S.L. - ECPv4.9.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cytognos, S.L.
X-ORIGINAL-URL:https://www.cytognos.com
X-WR-CALDESC:Events for Cytognos, S.L.
BEGIN:VTIMEZONE
TZID:"Europe/Paris"
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID="Europe/Paris":20211130T200000
DTEND;TZID="Europe/Paris":20211130T210000
DTSTAMP:20260425T184904
CREATED:20211109T095052Z
LAST-MODIFIED:20211109T144233Z
UID:19645-1638302400-1638306000@www.cytognos.com
SUMMARY:Webinar - Clinical value of measurable residual disease assessment in multiple myeloma - 11:00AM (PST)\, 2:00PM (EST)
DESCRIPTION:Join for a 1h webinar including a live Q&A session \nIn recent years\, Measurable Residual Disease (MRD) assessment in Multiple Myeloma (MM) has gained increasing relevance. New drugs and treatment strategies have emerged and have significantly modified the way we approach the disease. \nThanks to technological development\, classic detection approaches like conventional flow cytometry or ASO-PCR\, have evolved into next-generation methodologies that have supported MRD to become a more widely used prognostic indicator and clinical decision-making tool. \nSubstantial efforts are ongoing to recognize the value of the standardization of MRD assessment. Following standardized methodologies can accelerate the obtention of clinically meaningful results and thus\, lead to further optimized therapies. \nLearning Objectives: \n\nAnalyze the bases of MRD detection in MM patients with available methodologies.\nDiscuss the clinically useful information that MRD provides and how MRD testing can be incorporated in routine clinical practice.\nAssess recent advances and new opportunities in the field of Multiple Myeloma patient monitoring.\n\nJuan Flores-Montero MD\, PhD works as Postdoctoral Researcher at the Central Cytometry Service at the University of Salamanca and the Cancer Research Center. His main research focus are the development and standardization of flow cytometric approaches for the diagnosis\, classification and monitoring of hematologic malignancies as well as monitoring of the immune system to assess its role on disease onset and progression. He is a member of the EuroFlow™ consortium\, an active member of the Iberian Cytometry Society (SIC) and current Board member of the European Society for Clinical Cell Analysis (ESCCA). \n2 PM GMT – 5 (New York\, NY\, USA)\n11 AM GMT – 8 (Los Angeles\, CA\, USA)\n7 PM GMT + 0 (London\, UK)\n8 PM GMT + 1 (Madrid\, Spain)\n3 AM GMT + 8 (Beijing\, China)\n6 AM GMT + 11 (Sydney\, Australia)\n4 PM GMT – 3 (Rio de Janeiro\, Brazil) \n.fusion-button.button-1 .fusion-button-text\, .fusion-button.button-1 i {color:#bb0000;}.fusion-button.button-1 {border-width:1px;border-color:#bb0000;}.fusion-button.button-1 .fusion-button-icon-divider{border-color:#bb0000;}.fusion-button.button-1:hover .fusion-button-text\, .fusion-button.button-1:hover i\,.fusion-button.button-1:focus .fusion-button-text\, .fusion-button.button-1:focus i\,.fusion-button.button-1:active .fusion-button-text\, .fusion-button.button-1:active{color:#bb0000;}.fusion-button.button-1:hover\, .fusion-button.button-1:focus\, .fusion-button.button-1:active{border-width:1px;border-color:#bb0000;}.fusion-button.button-1:hover .fusion-button-icon-divider\, .fusion-button.button-1:hover .fusion-button-icon-divider\, .fusion-button.button-1:active .fusion-button-icon-divider{border-color:#bb0000;}.fusion-button.button-1 .fusion-button-text {text-transform:uppercase;}.fusion-button.button-1{width:auto;}Check your local time\n\n.fusion-button.button-2 .fusion-button-text\, .fusion-button.button-2 i {color:#bb0000;}.fusion-button.button-2 {border-width:1px;border-color:#bb0000;}.fusion-button.button-2 .fusion-button-icon-divider{border-color:#bb0000;}.fusion-button.button-2:hover .fusion-button-text\, .fusion-button.button-2:hover i\,.fusion-button.button-2:focus .fusion-button-text\, .fusion-button.button-2:focus i\,.fusion-button.button-2:active .fusion-button-text\, .fusion-button.button-2:active{color:#bb0000;}.fusion-button.button-2:hover\, .fusion-button.button-2:focus\, .fusion-button.button-2:active{border-width:1px;border-color:#bb0000;}.fusion-button.button-2:hover .fusion-button-icon-divider\, .fusion-button.button-2:hover .fusion-button-icon-divider\, .fusion-button.button-2:active .fusion-button-icon-divider{border-color:#bb0000;}.fusion-button.button-2 .fusion-button-text {text-transform:uppercase;}.fusion-button.button-2{width:auto;}Register here\n
URL:https://www.cytognos.com/event/webinar-clinical-value-of-measurable-residual-disease-assessment-in-multiple-myeloma-1100am-pst-200pm-est/
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/png:https://www.cytognos.com/wp-content/uploads/webinar-juan-flores-21-min.png
END:VEVENT
END:VCALENDAR